Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2006

CytoGenix’ Gene Silencing ssDNA Technology Patent Allowed in Europe and India

  • CytoGenix received notices of allowances for grant of patent applications covering the technology for expressing ssDNA in vivo from the Indian and European Community Patent Offices. These notices follow the previous notice of allowance for these applications from the Peoples Republic of China.

    Filed in 1999 and 2000, these patents cover the company's single-strand DNA expression system covered by a U.S. patent. It is used in the company's Simplivir™ antiherpes and CY303 anti-inflammation products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »